Skip to main content

AstraZeneca

Harbour BioMed Joins Stock Connect After Seven Profitable Half-Years

Harbour BioMed Joins Stock Connect After Seven Profitable Half-Years

Shanghai – September 09, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.

First-half 2026 revenue rises 20.9% to $122.5 million

Harbour BioMed recorded total revenue of approximately US$122.5 million in the first half of 2026, up 20.9% year-over-year. Adjusted net profit reached approximately US$71.6 million, marking seven consecutive profitable half-years. Cash and cash equivalents stood at approximately US$359.2 million as of June 30, 2026.

IDEAYA Sets Phase 3 Design for IDE849 After FDA Type C Meeting

IDEAYA Sets Phase 3 Design for IDE849 After FDA Type C Meeting

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.